Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $54,600.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $10.92, for a total value of $54,600.00. Following the transaction, the director now directly owns 806,283 shares of the company’s stock, valued at approximately $8,804,610.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total value of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total transaction of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.

Olema Pharmaceuticals Trading Down 9.3 %

Shares of Olema Pharmaceuticals stock opened at $9.84 on Friday. The business’s fifty day moving average price is $11.34 and its 200 day moving average price is $12.83. Olema Pharmaceuticals, Inc. has a twelve month low of $5.02 and a twelve month high of $17.79. The stock has a market capitalization of $550.35 million, a P/E ratio of -4.56 and a beta of 2.10.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). As a group, sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on OLMA. Citigroup assumed coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, January 30th. They set a “buy” rating and a $20.00 price objective on the stock. HC Wainwright raised their price objective on Olema Pharmaceuticals from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday. The Goldman Sachs Group assumed coverage on Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 target price for the company. Finally, Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $21.43.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OLMA. Public Employees Retirement System of Ohio acquired a new stake in shares of Olema Pharmaceuticals in the third quarter worth $35,000. China Universal Asset Management Co. Ltd. acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at about $130,000. SG Americas Securities LLC bought a new position in Olema Pharmaceuticals in the third quarter worth about $142,000. Finally, Entropy Technologies LP acquired a new position in Olema Pharmaceuticals in the first quarter worth approximately $161,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.